130 studies found for:    "HIV Preventive Vaccine" [CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
"HIV Preventive Vaccine" [CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
Conditions: HIV Seronegativity;   HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59;   Biological: DNA-C2 + MVA-C;   Biological: DNA-C2 + MVA-C + gp140/MF59
2 Completed Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults
Condition: HIV Infections
Interventions: Biological: SAAVI DNA-C2 vaccine;   Biological: SAAVI MVA-C vaccine;   Biological: Placebo
3 Completed Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT);   Biological: rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT);   Biological: Empty TBC-FPV;   Biological: TBC-MVA and TBC-FPV
4 Completed Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults
Condition: HIV Infections
Interventions: Biological: ALVAC(2)120(B,MN)GNP (vCP1452);   Biological: gp160 MN/LAI-2;   Biological: ALVAC(1)120(B,MN)GNP (vCP1433);   Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65)
5 Completed Screening Protocol for HIV Vaccine Studies
Conditions: HIV Seronegativity;   HIV Infections
Intervention:
6 Completed Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: HIV-1 gag DNA;   Biological: HIV-1 gag DNA plus IL-12 DNA adjuvant;   Biological: CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine);   Biological: Sodium chloride injection (0.9%)
7 Active, not recruiting Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals
Condition: HIV Infections
Interventions: Biological: VRC-HIVDNA-016-00-VP;   Biological: VRCHIVADV014-00-VP
8 Completed Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VRC-HIVADV014-00-VP;   Biological: VRC-HIVDNA016-00-VP
9 Completed Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: MRKAd5 HIV-1 gag/pol/nef
10 Withdrawn Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: Aluminum hydroxide;   Biological: QS-21;   Biological: MN rsgp120/HIV-1
11 Completed The Effectiveness of Human Antibodies in Influencing an AIDS-Like Disease in Monkeys
Condition: HIV Infections
Interventions: Biological: gp160 MN/LAI-2;   Biological: Aluminum hydroxide
12 Not yet recruiting Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B
Condition: HIV Infections
Intervention: Biological: Experimental
13 Completed Safety of an HIV DNA Vaccine Given to HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: pGA2/JS2 Plasmid DNA Vaccine
14 Completed A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult Volunteers
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV gp160MN (vCP125);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65);   Biological: rgp120/HIV-1 SF-2
15 Completed A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials
Condition: HIV Infections
Intervention: Other: Observation
16 Completed Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: Clade B gag DNA/PLG and env DNA/PLG Microparticles;   Biological: Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant
17 Completed Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052
Condition: HIV Infections
Intervention: Biological: VRC-HIVADV014-00-VP
18 Completed Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC-HIV (vCP205)
19 Completed Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant
Condition: HIV Infections
Interventions: Biological: rgp120/HIV-1 SF-2;   Biological: MTP-PE/MF59
20 Completed Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults
Condition: HIV Infections
Interventions: Biological: VRC-HIVADV027-00-VP;   Biological: VRC-HIVADV038-00-VP;   Biological: VRC-HIVDNA044-00-VP

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years